HOME

OUR RESEARCH

RNAi

R&D DEPARTMENTS

PUBLICATIONS

OUR PARTNERS

CONTACTS

21.06.2010  The team is growing bigger
As we are constantly increasing our research potential, four new scientist were recruited to our R&D department. The total number of researchers working on innovative drugs exceeded 40.

17.06.2010  The new R&D laboratories are now officially opened!
We were honored to host our collaborators: the most remarkable scientists, entrepreneurs and politicians, who visited our headquarters to celebrate the official opening of Celon Pharma's new R&D laboratories. We took this opportunity to present our ideas on development of modern innovative drugs and to discuss future perspectives of drug research.

       

   

17.05.2010  Visit our booth at Bio-Forum 2010!
We will be happy to meet you in Lodz at the biggest international event for bio-tech society in Central Europe - Bio-Forum 2010 (19-20.05.2010). You are welcome to visit our booth to obtain information on company's profile, discuss our current R&D projects and, the last but not least, taste our freshly ground coffee.

12.05.2010  CCelon Pharma presented on The Multidisciplinary Conference on Drug Research
The latest results of company's studies on innovative drugs of potential use in oncology were reported on The Multidisciplinary Conference on Drug Research in Zakopane (10-12.05.2010).

26.03.2010  Celon Pharma launches NMR Spectrometer
Celon Pharma successfully launched Varian Unity Inova 300 MHz NMR Spectrometer as a support for the rapidly growing R&D and QC Departments.

03.02.2010  Celon Pharma tightens collaboration with Military Institute of Health in Warsaw
Another project concerning Wnt signaling pathway in oncology has been launched in co-operation with Military Institute of Health in Warsaw. The collaborators' research will focus on ovary carcinoma.

06.01.2010  Celon Pharma and Bydgoszcz Center of Oncology sign the cooperation agreement
Celon Pharma and Prof. Lukaszczyk Center of Oncology in Bydgoszcz will join their efforts in better understanding of Wnt signaling pathway, which is one of the most attractive drug targets in oncology.

01.12.2009  Celon Pharma presented at AACR-NCI-EORT International Conference in Boston
Celon Pharma presented a poster with its preliminary results on the role of beta-catenin in colorectal carcinogenesis at “Molecular Targets and Cancer Therapeutics” conference on 15-19.11.2009, Boston, USA. You are welcome to take a look at the poster in the Publications section.

27.11.2009  R&D departments move to new laboratories
Medicinal Chemistry, Molecular Biology and Drug Product Development Departments move to new laboratories located next to the manufacturing facility. This new location offers larger lab space and better communication between R&D units. The removal has just begun and will be completed by the end of the year.

23.09.2009  Better and faster drug manufacturing thanks to UE grant
The UE Innovative Economy Grant (POIG 4.4) for the construction of a new manufacturing facility has been awarded to Celon Pharma. A new production line will allow us to expand our manufacturing capabilities.

14.08.2009  Another research projects accepted for UE financial support
Celon Pharma obtained UE grants for ten different research projects of total support beyond 50 million zlotys! These will reinforce studies in company's main research areas: siRNA, oncology, metabolic diseases and neurology.

15.07.2009  A new device in Medicinal Chemistry Unit
The first purchase financed from UE Innovative Economy Grant (POIG 4.2) has been made: Celon Pharma's Medicinal Chemistry Unit is now equipped with a new device - the NMR spectrometer.

30.06.2009  Celon Pharma has been granted a financial support from UE Innovative Economy program (POIG 4.2.)!
The UE funds will be spend on modification and extension of company's R&D department by creation of two new research facilities: The Laboratory of Oligonucleotides Synthesis and The Laboratory of Pre-clinical Studies on Innovative Drugs. Our new laboratories will smooth the progress of drug development in pre-clinical phase, enabling us to provide patients with efficient therapeutics earlier.

5.06.2009  All good things come to an end
It is fair to state that Bio–Forum 2009 – the unique meeting of Central European Bio–Tech society has been a great success! More than 1200 experts from bio–industry and academia gathered together in Lodz to share views and ideas. Celon Pharma, which is proud to be the sponsor of this event, hosted many of participants at its booth, offering not only the first–hand information on company’s research areas but also a cup of excellent coffee.

12.05.2009  Meet us at Bio-Forum 2009 – the biggest international event for bio-tech society in Central Europe
Celon Pharma is a sponsor of BioForum 2009. We feel strong need of promoting exchange of skills and know-how between business and academia. BioForum is an unique event that enable this exchange to become real. We will be happy to meet you there and talk about any collaboration regarding: new drug targets, know-how in RNA chemistry, experience in oligonucleotides stability and delivery, animal models for oncology research and of metabolic and CNS diseases.

08.05.2009  New in vivo studies have been launched
Celon Pharma started prelimiary in vivo experiments using small molecule drug candidates for treatment of diabetes and metabolic disorders.

04.05.2009  We are growing bigger!
Celon Pharma acquired new space for its R&D Biology and Medicinal Chemistry Laboratories.
The design and arrangements of new work space have been already launched to prepare it for the full functionality on the brake of summer and fall.

06.05.2009  Celon Pharma is a winner of Quality International 2009 contest.
Celon Pharma receives the silver medal in competition for a company of the highest quality in 2009 organized by Business Forum. This award confirmed that our products, research and development projects are the state-of-the-art in Poland.

20.03.2009  Celon Pharma and International Institute of Molecular and Cellular Biology sign the agreement for cooperation.
Celon Pharma and International Institute of Molecular and Cellular Biology will collaborate I the project of in vitro and in vivo screens of new innovative drug candidates used in a treatment of Alzheimer's disease.

16.03.09  Celon Pharma and Adam Mickiewicz University in Poznan sign the agreement for collective research projects.
Cooperation between Celon Pharma and Adam Mickiewicz University regarding in vitro screening of new compounds – the putative innovative anticancer drugs.

13.03.2009  New quality stage – Celon Pharma passed control audit for: ISO 9001, ISO 14001, ISO 18001/OHSAS 2007.
As a result of positive Integrated Management System audit which took place on 13th March 2009 Laboratory of Research and Development of Biotechnological Drugs has maintain the following certificates: ISO 9001, ISO 14001, ISO 18001/OHSAS 2007.

22.12.2008  Celon Pharma is beneficiary of 5 mln PLN from UE program Innovative Economy, priority: Research and development of new technologies (1.4-4.1)
Celon Pharma and Polish Agency for Enterprise Development (PARP) sign agreement for financial support of research project of innovative anticancer drug, which inhibits transcriptional activity in cancer cells.

24.11.2008  New collaboration in oncology research has been established
We established the collaboration with Military Institute of Health in Warsaw to exchange knowledge and experience in the field of Wnt signaling pathway as a drug target in oncology.

20.10.2008  Meet us at 20th EORTC-NCI-AACAR Symposium!
Join and meet us at 20th Symposium on ”Molecular Targets and Cancer Therapeutics” in Geneva, Switzerland. This symposium, hosted by EORTC, NCI and AACR, will bring together academics and scientists and representatives from the pharmaceutical industry to discuss innovation in drug development, target selection and the impact of new discoveries in molecular and cell biology.

20.10.2008  Celon Pharma signs agreement for anticancer drug research project financed by Technology Initiative I a programme of the Minister of Science and Higher Education.
Celon Pharma and National Centre for Research and Development signs agreement for financing research of innovative drugs based on RNAi technology. This project is focused on finding active and specific siRNA which inhibits human Wnt-1 gen expression in cancer cells.

27.06.2008  New collaboration in oncology research has been established
We started the collaboration with Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology in Warsaw in the field of Wnt/ß-catenin pathway proteomics. We joined our forces to verify the expression of chosen signaling proteins in different types of breast cancer.

30.04.2008  New quality stage - receiving certificates: ISO 9001, ISO 14001, ISO 18001/OHSAS 2007.
As a result of positive Integrated Management System audit which took place on 15th and 16th. April 2008 Laboratory of Research and Development of Biotechnological Drugs has received the following certificates: ISO 9001, ISO 14001, ISO 18001/OHSAS 2007.

20.04.2008  Promising results of the first preclinical in vivo application of siRNA silencing the Wnt-1 gene in mice
Celon Pharma in collaboration with Experimental Medicine Centre in Białystok received the first results of in-vivo tests of siRNA as an anticancer therapeutic. The treatment of nude mice through systemic application (subcutaneous or intraperitoneal) of PEI-complexed siRNA resulted in the delivery of intact siRNA into subcutaneous tumor xenografts and significant inhibition of tumor growth.

19.12.2007  Celon Pharma publishing results of preclinical studies using siRNA in Cancer Biology and Therapy.
"Silencing of Wnt-1 by siRNA induces apoptosis of MCF-7 human breast cancer cells" (volume 7, issue 2 February 2008) is the first original publication of a preclinical studies in silencing of the Wnt-1 gene. Our results significantly indicate that anti-Wnt-1 siRNA inhibits Wnt-1 signaling, inducing apoptosis in human breast cancer cells and thus may serve as a potential anticancer drug.

http://www.landesbioscience.com/journals/cbt/article/5300

11-10-2007  Celon research at Cancer Therapeutics Conference.
Celon Pharma Ltd presented results of preclinical studies using siRNA in EGFR pathway inhibition. Data were shown during Cancer Therapeutics: The Road Ahead Conference on Capri from October 8th to 10th in 2007.

Epidermal growth factor receptor family members (ErbBs) are currently major targets of anticancer strategies and identifying the contribution of ErbBs to tumorigenesis is crucial for development of anti-ErbB therapies. Overexpression of EGFR may serve as a prognostic marker with respect to survival in advance breast cancer and recurrence in operable breast tumors. The downregulation of ErbBs members by RNA interference, especially in breast cancer offers a new mode for high effective and selective inhibition of specific gene expression.

03-07-2007  Celon Pharma Ltd. goes to in vivo experiments.
Celon Pharma is planning to start first in vivo experiments using siRNA as an anticancer drug this year.

Planned in this project experiments are continuation of earlier in vitro screening tests, which purposing the preliminary estimation of the siRNA application in inhibition of tumor specific genes expression. The most interesting results were obtained for genes involved in uncontrolled proliferation, where we observed 70-90% inhibition of expression in comparison to negative control (scrambled siRNA). Also, we observed that silencing of target gene induced apoptosis at the level of 60-75%, and these results are similar to docetaxel which is commonly used in cancer therapy.

03-07-2007  Meet us at ECCO 14.
Celon Pharma Ltd will present results of preclinical studies with new innovative drug based on RNA interference technology. Data will be shown during 14th European Cancer Conference in Barcelona from September 23rd to 27th in 2007.

Utilization of phenomenon of interference is innovative manner of interaction on molecular targets RNA, that makes it possible selective effecting to oncogenes and incrementation of tumor. This project is focused on specific approach for tumor therapy, we brake process at the level of transcription of gene involved in tumorgenesis. Such is directed consistent with world trends of searches approach and development of tumor medicine. Celon Pharma is doing currently a research above the prototype of the anticancer drug based on the siRNA technology.

Celon Pharma Ltd
ul. Ogrodowa 2A
05-092 Lomianki, Kielpin

Home | Our research | RNAi | R&D departments | Publications | Our partners | Contacts

Celon Pharma © 2009  All Rights Reserved.
Designed by GREGMAR